[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad Autonoma de San Luis Potosí\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643451","buffered-versus-conventional-local-anesthesia-for-pain-and-anxiety-reduction-in-school-aged-children-with-pulpitis-100643451",false,"NCT07638254","Buffered Versus Conventional Local Anesthesia for Pain and Anxiety Reduction in School-Aged Children With Pulpitis","Efficacy of Buffered Versus Conventional Local Anesthesia for Reducing Pain and Anxiety During Dental Treatment in School-Aged Children Diagnosed With Pulpitis: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Children aged 6 to 12 years\n* Diagnosis of irreversible pulpitis due to dental caries in primary maxillary molars\n* American Society of Anesthesiologists (ASA) Physical Status Classification I\n* Cooperative or definitely cooperative behavior according to Frankl Behavioral Scale (Frankl III or IV)\n* Written informed consent provided by parent or legal guardian, and child assent when applicable\n* No use of analgesic or anti-inflammatory medication within 24 hours prior to the procedure\n\nExclusion Criteria:\n\n* Known allergy to any component of local anesthetic solution\n* History of negative or traumatic dental experiences within the previous 12 months that may interfere with behavioral assessment\n* Radiographic evidence of periapical pathology associated with the affected tooth\n* Presence of localized abscess or acute spreading infection at the injection site",true,"ALL","6 Years","12 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this clinical trial is to evaluate whether buffered local anesthesia is more effective than conventional local anesthesia in reducing pain responses in school-aged children requiring dental treatment for pulpitis. The study will also assess differences in physiological and self-reported indicators of pain and anxiety, as well as anesthetic onset and duration.\n\nThe main questions it aims to answer are:\n\nDoes buffered local anesthesia reduce behavioral pain scores measured by the FLACC scale compared to conventional local anesthesia? Does buffered local anesthesia improve physiological and psychometric indicators of pain and anxiety during dental procedures?\n\nMethodology: The researchers will compare buffered local anesthesia with conventional local anesthesia during routine dental treatment procedures such as pulpotomy or pulpectomy in primary molars.\n\nParticipants will:\n\nReceive either buffered or conventional local anesthesia during dental treatment Undergo pulpotomy or pulpectomy depending on clinical diagnosis Be monitored for pain and anxiety using FLACC scale, heart rate, skin conductance, and Wong-Baker Faces Pain Scale at different stages of treatment Have the onset and duration of anesthesia recorded during and after the procedure Be followed until recovery of soft tissue sensation after treatment",[28],"Pulpitis",[30,31,32],"Anesthesia, Dental","Anesthesia, Local","Buffers","RECRUITING","2026-06-04",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":37},"2026-03-02",{"date":41,"type":22},"2026-10",{"name":43,"class":44},"Universidad Autonoma de San Luis Potosí","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100638249","phase-2-melissa-officinalis-aromatherapy-for-dental-anxiety-in-children-100638249","NCT07592130","Melissa Officinalis Aromatherapy for Dental Anxiety in Children","Anxiolytic Effect of Inhaled Melissa Officinalis Essential Oil During Mandibular Local Anesthesia in Pediatric Dental Patients: A Randomized Controlled Clinical Trial","No acronym","Inclusion Criteria:\n\n* Children aged 6 to 10 years at the time of enrollment.\n* Male or female pediatric patients in good general physical and mental health.\n* Require mandibular local anesthesia (inferior alveolar nerve block) for pulpotomy or pulpectomy of at least one primary molar.\n* No previous experience with dental local anesthesia.\n* Behavior classified as \"positive\" or \"negative but accepting\" (categories 2 or 3) according to the Frankl Behavior Rating Scale during the initial examination.\n* Ability of the child to understand simple verbal instructions appropriate for age.\n* Parent or legal guardian able and willing to sign written informed consent.\n* Child willing to provide verbal assent to participate in the study.\n\nExclusion Criteria:\n\n* History of previous dental local anesthesia.\n* Presence of dental emergencies (e.g., acute infection, severe pain, or swelling) requiring urgent treatment.\n* Known diagnosis of neurological, psychiatric, developmental, or behavioral disorders that may interfere with cooperation or with the assessment of anxiety and pain.\n* Systemic diseases or medical conditions (American Society of Anesthesiologists \\[ASA\\] physical status III or higher) that increase procedural risk or preclude participation according to the investigator's judgment.\n* Current acute upper respiratory conditions, such as common cold, rhinitis, sinusitis, or nasal allergy that could alter the sense of smell or breathing comfort.\n* Known allergy, hypersensitivity, or adverse reaction to Melissa officinalis, other Lamiaceae plants, essential oils, or components of the products used in the study.\n* Use of anxiolytics, antidepressants, sedatives, or other psychotropic medications within the last 30 days.\n* Behavior rated as definitely negative (Frankl category 1) or definitely positive (Frankl category 4) at baseline.\n* Inability of parents or guardians to understand the study information or provide informed consent.\n* Participation in another clinical trial within the previous 30 days.","10 Years",{"count":56,"type":22},45,[58],"PHASE2","This clinical study will look at whether a plant-based essential oil called \"Melissa officinalis\" (lemon balm) can help reduce fear and stress in children during dental treatment. Children between 6 and 10 years old who need a mandibular injection for a pulpotomy or pulpectomy will be invited to participate. They will be randomly assigned to one of three groups: one group will receive aromatherapy with \\*Melissa officinalis\\* from brand A, another group will receive the same essential oil from brand B, and a third group will receive the usual behavioral management used in pediatric dentistry, but without aromatherapy.\n\nThe essential oil will be diffused in the dental room so that the child can gently inhale the aroma starting a few minutes before the injection and throughout the procedure. The study team will measure the child's dental anxiety using a child-friendly questionnaire with drawings of faces, observe pain behaviors during the injection, and record the child's own rating of pain with a faces scale. Heart rate and oxygen saturation will also be monitored as objective signs of stress. The goal is to find out whether \"Melissa officinalis\" aromatherapy is a safe, simple, non-invasive way to make dental visits less stressful and more comfortable for children, and whether there are meaningful differences between the two commercial products.",[61,62],"Emotional Anxiety and Stress During Pediatric Dental Treatment","Dental Anesthesia",[64,65,66,67,68],"Pediatric dental anxiety","Aromatherapy","PediMelissa officinalis","Essential oils","Pediatric oral anesthesia","NOT_YET_RECRUITING","2026-05-11",{"date":72,"type":37},"2026-05-18",{"date":74,"type":22},"2026-06-15",{"date":76,"type":22},"2027-02-25",{"name":43,"class":44},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":16,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":45},"100556734","proteinopathies-expression-in-skin-of-neurodegenerative-disorders-100556734","NCT06528964","Proteinopathies Expression in Skin of Neurodegenerative Disorders","Expression of Proteinopathies in Skin Biopsies of Patients With Neurodegenerative Disorders","Inclusion Criteria for patients:\n\n* Patients 45 years and older\n* Men and women\n* Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus\n* Patients that voluntarily accept to participate in the study and accept the consent form\n\nInclusion Criteria healthy control subjects:\n\n* People 45 years and older\n* Men and women\n* Subjects can be related to a patient but not by blood (for example spouse of a patient)\n* Subjects don't have direct family history of a neurodegenerative control\n* Subjects don't have any clinical findings suggesting dementia\n* Subjects voluntarily accept to participate in the study and accept the consent form\n\nExclusion Criteria:\n\n* Patients or controls that have a personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia or HIV related dementia\n* Patients in which the diagnosis is not clear or hasn't been confirmed\n* Patients or controls that have a neuroinfection\n* Patients or controls that a diagnosed skin disease\n* Patients that have an \"atypical\" presentation of the disease\n* Patients or controls that have diagnosis of a coagulopathy","45 Years",{"count":87,"type":22},40,"OBSERVATIONAL","The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \\[TDP43\\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is:\n\n* Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects?\n\nSkin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.",[91,92,93,94,95,96],"Alzheimer Disease","Frontotemporal Dementia","Parkinson Disease","Atypical Parkinsonism","Amyotrophic Lateral Sclerosis","Normal Pressure Hydrocephalus",[98,99,100,101],"Alpha Synuclein Pathology","Tauopathies","TDP-43 Proteinopathies","Beta-Amyloid","2024-12-13",{"date":104,"type":37},"2024-12-16",{"date":106,"type":37},"2023-12-20",{"date":108,"type":22},"2026-11-01",{"name":43,"class":44},""]